Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a regenerative medicine company headquartered in Canton, Massachusetts that develops and commercializes advanced wound care and surgical medicine products. The company manufactures biologically derived tissue scaffolds, allografts, and bioengineered substitutes designed to promote wound healing and tissue repair. Its product portfolio includes Apligraf and Dermagraft for diabetic foot ulcers and venous leg ulcers, placental allografts such as Affinity and Novachor, and antimicrobial wound barriers including the PuraPly product line. Additional offerings include TransCyte for burn treatment and various biosynthetic matrices for surgical applications.

The company's primary revenue streams come from the advanced wound care market, where its products serve hospitals, wound care centers, ambulatory surgical centers, and physician offices through a direct sales force and independent distribution agencies. Organogenesis also maintains a pipeline of development-stage products, including ReNu, a cryopreserved cell suspension in Phase 3 trials for knee osteoarthritis treatment.

The company operates primarily in the United States market. With a market capitalization of approximately $500 million, Organogenesis operates at a mid-sized scale within the specialty pharmaceutical and regenerative medicine sector, competing in markets where advanced wound care and tissue engineering products command premium pricing relative to conventional alternatives.